<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401737</url>
  </required_header>
  <id_info>
    <org_study_id>NVR3-778-101B</org_study_id>
    <nct_id>NCT02401737</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients</brief_title>
  <official_title>A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novira Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <authority>Taiwan: Taiwan Food and Drug Administration (TFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b trial will assess the dose-related safety and PK profile of different doses of
      NVR 3-778 in patients with chronic hepatitis B. Additionally,changes in patients' serum HBV
      DNA levels and other virologic efficacy parameters will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1b assessments of the dose-related safety, PK, and initial antiviral efficacy of
      NVR 3-778 in hepatitis B patients will also be conducted at approximately 14 different sites
      to meet enrollment goals of 54-84 chronic hepatitis B patients.

      To promote objective safety and tolerance assessments during this trial, study subjects, and
      site personnel administering the study drug and performing the clinical assessments on the
      subjects, will be blinded to individual subjects' treatments assignments (active NVR 3-778
      or placebo doses), for all treatment cohorts in the study. Study advancement to subsequent
      patient cohorts will require satisfactory interim reviews of available cumulative safety
      data by the Safety Review Committees (SRC), using the safety criteria and review procedures
      described in the protocol. Also, there will be one interim review of safety data by an
      independent Safety Monitoring Board (SMB), as described in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compared with baseline, decline of serum HBV-DNA in the value</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>NVR 3-778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVR 3-778 in varying doses of capsules by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for NVR 3-778</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVR 3-778 and Pegasys</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVR 3-778</intervention_name>
    <arm_group_label>NVR 3-778</arm_group_label>
    <arm_group_label>NVR 3-778 and Pegasys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for NVR 3-778</intervention_name>
    <description>Sugar pill manufactured to mimic the NVR 3-778 capsule</description>
    <arm_group_label>Placebo for NVR 3-778</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <arm_group_label>NVR 3-778 and Pegasys</arm_group_label>
    <arm_group_label>Pegasys</arm_group_label>
    <other_name>peginterferon alfa-2a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2.
        Patients must be HBeAg positive and have chronic hepatitis B with no history of clinical
        decompensation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandy Liaw</last_name>
    <email>sliaw@noviratherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 8, 2015</lastchanged_date>
  <firstreceived_date>March 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
